BioLineRx Ltd. (BLRX) Q1 2025 Earnings Call Transcript

BioLineRx (BLRX) reported Q1 2025 earnings, highlighting the out-licensing agreement with Ayrmid Pharma for APHEXDA, which generated $0.3 million in royalty revenues on $1.4M in sales. The company has reduced operating cash burn by over 70% to under $12 million annually and ended the quarter with $26.4 million in cash, funding operations through the second half of 2026. BioLineRx is focused on evaluating and in-licensing early clinical-stage assets in oncology and rare diseases, while also supporting the Columbia University-sponsored Phase 2b trial of motixafortide in pancreatic cancer, with updated pilot phase data to be presented at ASCO showing promising response rates and increased T cell density in tumors.

Analysis

BioLineRx has strategically repositioned itself following the out-licensing of its FDA-approved drug APHEXDA (motixafortide) to Ayrmid Pharma for multiple myeloma stem cell mobilization. This transaction has significantly reduced annual operating cash burn by over 70% to under $12 million and bolstered the balance sheet, with $26.4 million in cash as of March 31, 2025, providing a projected runway through the second half of 2026. APHEXDA generated $1.4 million in sales in Q1 2025 under Ayrmid, resulting in $0.3 million in royalty revenue for BioLineRx, with the company anticipating further growth, milestones up to $87 million, and tiered royalties. BioLineRx is now focused on in-licensing early clinical-stage or late preclinical assets in oncology and rare diseases, leveraging its development expertise, with an announcement expected later this year. Simultaneously, development of motixafortide continues in Pancreatic Ductal Adenocarcinoma (PDAC) through the Columbia University-sponsored Phase 2b CheMo4METPANC trial; highly encouraging pilot phase data, showing a 64% partial response rate and 9.6 months median progression-free survival, will be updated at the upcoming ASCO meeting, with a trial interim analysis planned for 2026. The company's Q1 2025 financials reflect this transition, with revenues of $0.3 million primarily from APHEXDA royalties, a stark decrease from $6.9 million in Q1 2024 which included upfront payments from a separate licensing deal, alongside substantially lower R&D ($1.6 million) and sales & marketing expenses ($0).

Key Decisions for Investors

• Investors should monitor near-term catalysts such as the upcoming ASCO presentation detailing motixafortide's promising PDAC pilot data and the anticipated announcement of new in-licensed assets by year-end, as these could be significant value drivers.
• Evaluate the long-term revenue stream potential from APHEXDA royalties and milestones, including its potential expansion into sickle cell disease mobilization, alongside the considerable upside from the CheMo4METPANC PDAC trial, for which an interim analysis is expected in 2026.
• Assess the company's execution on its new strategy of in-licensing and developing early-stage assets, noting that while the restructured operations provide a stable financial footing with a cash runway through H2 2026, success hinges on prudent asset selection and clinical advancement.